Actinium Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
$0.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly53.4MTarget: Sufficient to fund operations into mid-2027
Net Loss Annually-33.9MTarget: Narrowing losses through disciplined R&D and SG&A spending
Stockholders' Equity Quarterly2.3MTarget: Regain compliance with NYSE American continued listing standards (> $2.0M or $6.0M depending on standard)
Watch Items
- NYSE American Continued Listing Standards Compliance PlanTrigger: Submission deadline of June 26, 2026; Plan Period Deadline of November 27, 2027Action: Submit a comprehensive compliance plan to NYSE American detailing actions to regain compliance with Sections 1003(a)(ii) and (iii).
- Iomab-B Additional Phase 3 Clinical Trial InitiationTrigger: FDA alignment on a broader patient population (adults aged 18+ with active AML blast counts 5% to 20%)Action: Secure a strategic partner to advance Iomab-B through the newly required head-to-head Phase 3 trial demonstrating overall survival (OS) benefit.
- ATNM-400 Clinical AdvancementTrigger: Initial clinical data readouts and IND-enabling milestones in 2H 2026Action: Advance the first-in-class Actinium-225 antibody radioconjugate into clinical trials for solid tumors (prostate, lung, breast).
- cGMP Manufacturing Facility OperationalizationTrigger: Targeted operational status in 2H 2026Action: Complete construction and validation of the internal cGMP facility to support clinical and commercial-scale isotope production.
Research as of 19 Jun 2026